A randomized phase II clinical trial evaluating the safety and efficacy of initial dose adjustment of zolbetuximab plus chemotherapy in patients with HER2-negative and CLDN18.2-positive unresectable advanced or recurrent gastric, gastroesophageal junction cancer or esophageal adenocarcinoma (GENTLE-Z).

被引：0
|
作者：
Okunaka, Mashiro
Furuoka, Momoka
Wakabayashi, Masashi
Furuya, Hideki
Bando, Hideaki
Shitara, Kohei
Nakayama, Izuma
机构：
[1] Natl Canc Ctr Hosp East, Dept Pharm, Kashiwa, Japan
[2] Natl Canc Ctr Hosp East, Kashiwa, Japan
[3] Natl Canc Ctr Hosp East, Div Promot Drug & Diag Dev, Kashiwa, Japan
[4] Natl Canc Ctr Hosp East, Clin Res Support Off, Kashiwa, Japan
[5] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Japan
[6] Natl Canc Ctr Hosp East, Gastrointestinal Oncol Dept, Kashiwa, Japan
[7] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Chiba, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.4_suppl.TPS504
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：TPS504 / TPS504
页数：1
相关论文
共 41 条
  • [21] Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial
    Boku, Narikazu
    Omori, Takeshi
    Shitara, Kohei
    Sakuramoto, Shinichi
    Yamaguchi, Kensei
    Kato, Ken
    Kadowaki, Shigenori
    Tsuji, Kunihiro
    Ryu, Min-Hee
    Oh, Do-Youn
    Oh, Sang Cheul
    Rha, Sun Young
    Lee, Keun-Wook
    Chung, Ik-Joo
    Sym, Sun Jin
    Chen, Li-Tzong
    Chen, Jen-Shi
    Bai, Li-Yuan
    Nakada, Takashi
    Hagihara, Shunsuke
    Makino, Reina
    Nishiyama, Eiji
    Kang, Yoon-Koo
    GASTRIC CANCER, 2024, 27 (06) : 1287 - 1301
  • [22] Updated efficacy and safety results from phase III SPOTLIGHT study evaluating zolbetuximab+mFOLFOX6 as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2L, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
    Ajani, J. A.
    Lordick, F.
    Bang, Y-J.
    Enzinger, P. C.
    Ilson, D. H.
    Shah, M. A.
    van Cutsem, E.
    Xu, R-H.
    Aprile, G.
    Xu, J.
    Pazo Cid, R. A.
    Kang, Y-K.
    Yang, J.
    Moran, D.
    Bhattacharya, P.
    Matsangou, M.
    Arozullah, A.
    Park, J. W.
    Shitara, K.
    ANNALS OF ONCOLOGY, 2023, 34 : S1524 - S1525
  • [23] Efficacy and safety of neoadjuvant sintilimab in combination with FLOT chemotherapy in patients with HER2-negative locally advanced gastric or gastroesophageal junction adenocarcinoma: an investigator-initiated, single-arm, open-label, phase II study
    Li, Ning
    Li, Zhi
    Fu, Qiang
    Zhang, Bin
    Zhang, Jian
    Wan, Xiang-Bin
    Lu, Chao-Min
    Wang, Jin-Bang
    Deng, Wen-Ying
    Ma, Yi-Jie
    Bie, Liang-Yu
    Wang, Meng-Yu
    Li, Jing
    Xia, Qing-Xin
    Wei, Chen
    Luo, Su-Xia
    INTERNATIONAL JOURNAL OF SURGERY, 2024, 110 (04) : 2071 - 2084
  • [24] Updated efficacy and safety results from phase III SPOTLIGHT study evaluating zolbetuximab+mFOLFOX6 as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2L, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
    Ajani, J. A.
    Lordick, F.
    Bang, Y-J.
    Enzinger, P. C.
    Ilson, D. H.
    Shah, M. A.
    Van Cutsem, E.
    Xu, R-H.
    Aprile, G.
    Xu, J.
    Cid, R. A. Pazo
    Kang, Y-K.
    Yang, J.
    Moran, D.
    Bhattacharya, P.
    Matsangou, M.
    Arozullah, A.
    Park, J. W.
    Shitara, K.
    ANNALS OF ONCOLOGY, 2023, 34 : S1322 - S1322
  • [25] Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4)
    Boku, N.
    Ryu, M. -H.
    Kato, K.
    Chung, H. C.
    Minashi, K.
    Lee, K. -W.
    Cho, H.
    Kang, W. K.
    Komatsu, Y.
    Tsuda, M.
    Yamaguchi, K.
    Hara, H.
    Fumita, S.
    Azuma, M.
    Chen, L. -T.
    Kang, Y. -K.
    ANNALS OF ONCOLOGY, 2019, 30 (02) : 250 - 258
  • [26] Atezolizumab and trastuzumab plus chemotherapy in patients with HER2+locally advanced resectable gastric cancer or adenocarcinoma of the gastroesophageal junction: A multicenter, randomized, open-label phase II study.
    Peng, Zhi
    Zhang, Xiaotian
    Liang, Han
    Zheng, Zhichao
    Wang, Zhenning
    Liu, Hao
    Hu, Jiankun
    Sun, Yihong
    Zhang, Yanqiao
    Yan, Han
    Tong, Lin
    Xu, Jiahui
    Xie, Jessica
    Ji, Jiafu
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 312 - 312
  • [27] A randomized, double-blind, phase III study of pembrolizumab plus chemotherapy as first-line therapy in patients with HER2-negative, advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: KEYNOTE-859
    Qin, S.
    Tabernero, J.
    van Cutsem, E.
    Fuchs, C. S.
    Janjigian, Y. Y.
    Bhagia, P.
    Li, K.
    Adelberg, D.
    Bang, Y-J.
    ANNALS OF ONCOLOGY, 2020, 31 : S1316 - S1317
  • [28] Ramucirumab plus paclitaxel as switch maintenance versus continuation of oxaliplatin-based chemotherapy in patients (pts) with advanced HER2-negative gastric or gastroesophageal junction (GEJ) cancer: The ARMANI phase III trial.
    Pietrantonio, Filippo
    Randon, Giovanni
    Lonardi, Sara
    Garattini, Silvio Ken
    Tamberi, Stefano
    Giommoni, Elisa
    Di Donato, Samantha
    Fornaro, Lorenzo
    Brunetti, Oronzo
    De Vita, Ferdinando
    Frassineti, Giovanni Luca
    Chini, Claudio
    Spallanzani, Andrea
    Bethaz, Valerie
    Strippoli, Antonia
    Latiano, Tiziana Pia
    Cardellino, Giovanni Gerardo
    Palermo, Federica
    Miceli, Rosalba
    Di Bartolomeo, Maria
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA4002 - LBA4002
  • [29] Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial
    Kang, Yoon-Koo
    Chen, Li-Tzong
    Ryu, Min-Hee
    Oh, Do-Youn
    Oh, Sang Cheul
    Chung, Hyun Cheol
    Lee, Keun-Wook
    Omori, Takeshi
    Shitara, Kohei
    Sakuramoto, Shinichi
    Chung, Ik-Joo
    Yamaguchi, Kensei
    Kato, Ken
    Sym, Sun Jin
    Kadowaki, Shigenori
    Tsuji, Kunihiro
    Chen, Jen-Shi
    Bai, Li-Yuan
    Oh, Sung-Yong
    Choda, Yasuhiro
    Yasui, Hisateru
    Takeuchi, Kentaro
    Hirashima, Yoshinori
    Hagihara, Shunsuke
    Boku, Narikazu
    LANCET ONCOLOGY, 2022, 23 (02): : 234 - 247
  • [30] Management of nausea and vomiting (N/V) following first-line (1L) zolbetuximab plus chemotherapy treatment in claudin-18.2 (CLDN18.2)+, HER2-, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Analysis from the phase 3 SPOTLIGHT and GLOW studies.
    Shitara, Kohei
    Pophale, Rupesh
    Matsangou, Maria
    Park, Jung Wook
    Oh, Mok
    Bhattacharya, Pranob P.
    Ranganath, Radhika
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 372 - 372
12345